- Q3 2024 Immunoprecise Antibodies Ltd Earnings Call TranscriptMar 14, 2024$1.59 (-2.45%)Earnings
- Q2 2024 Immunoprecise Antibodies Ltd Earnings Call TranscriptDec 14, 2023$1.45 (+20.83%)Earnings
- Q1 2024 Immunoprecise Antibodies Ltd Earnings Call TranscriptSep 14, 2023$2 (-0.99%)Earnings
- Immunoprecise Antibodies Ltd To Participate in an Interview Hosted by Market Radius Research TranscriptJul 19, 2023
- Q4 2023 Immunoprecise Antibodies Ltd Earnings Call TranscriptJul 07, 2023$2.99 (-1.32%)Earnings
- Immunoprecise Antibodies Ltd at Smallcap Discoveries TranscriptJun 28, 2023
- Immunoprecise Antibodies Ltd at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Q3 2023 Immunoprecise Antibodies Ltd Earnings Call TranscriptMar 16, 2023$3.37 (-10.13%)Earnings
- Q2 2023 Immunoprecise Antibodies Ltd Earnings Call TranscriptDec 15, 2022$4.9 (-8.58%)Earnings
- Q1 2023 Immunoprecise Antibodies Ltd Earnings Call TranscriptSep 14, 2022$4.85 (-9.85%)Earnings
- Q4 2022 Immunoprecise Antibodies Ltd Earnings Call TranscriptJul 29, 2022$4.23 (-7.03%)Earnings
- Q2 2022 Immunoprecise Antibodies Ltd Earnings Call TranscriptDec 13, 2021$5.06 (-9.96%)Earnings
- Immunoprecise Antibodies Ltd LifeScience Webinar TranscriptApr 28, 2021
Immunoprecise Antibodies Ltd LifeScience Webinar Transcript
Good afternoon, and welcome back, everyone at the LifeScience online days. We are here with Ilse Roodink from ImmunoPrecise Antibodies. And she'll be telling you more about how therapeutic antibodies can help us against SARS-CoV-2, and her colleague, Debby Kruijsen, is also here as a Moderator. So please don't hesitate to ask your questions in the chats. Please go ahead, Ilse.
Thank you. Dear attendees, thank you for taking the time to learn more about IPA SARS-CoV-2 therapeutic antibody program and our capabilities that underpin the identification of synergistic antibody cocktails targeting the spike glycoprotein.
I would also like to thanks, Sartorius, for giving us the opportunity to discuss in more detail how we're leveraging our multi-species antibody discovery platforms and high-throughput antibody characterization abilities businesses enabled us to formulate sensible therapeutic portfolios at an early stage. Thank you, Helena, for the introduction.
This is
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)